Intensity Therapeutics, Inc.
61 Wilton Road, 3rd Floor
Westport, CT 06880
Our Company was founded in 2012 with the understanding that solid tumor cancers consist of well-defined visible growths and unseen micro-metastases. Cancer is thus both a regional and a systemic disease – each component has different physical properties. To have an effective treatment one must destroy (or remove) both the existing large observable tumors as well as all the unseen cell-based micrometastases (which can be anywhere in the body).
Our new approach treats both the macro and the micro aspects of solid tumor cancers. When injected directly into tumors (dose locally) our products have high tumor dispersion and cancer cell penetration properties. As a result, our drugs directly kill the cancer cells throughout the tumor. The local cell death results in the creation of antigenic sites that are highly personal to the patient dosed. This specific and unique new form of antigen presentation allows for better recognition of the cancer by the adaptive immune system. The resulting immune response helps to destroy the injected tumor and distal metastases (act globally).
- Advance our on-going phase 1/2 clinical study with our lead compound INT230-6
- Continue research on the next generation products
CT Employees: 4
World Employees: 4